144 related articles for article (PubMed ID: 23748007)
1. The effects of R683S (G) genetic mutations on the JAK2 activity, structure and stability.
Li F; Guo HY; Wang M; Geng HL; Bian MR; Cao J; Chen C; Zeng LY; Wang XY; Wu QY
Int J Biol Macromol; 2013 Sep; 60():186-95. PubMed ID: 23748007
[TBL] [Abstract][Full Text] [Related]
2. Disruption of E627 and R683 interaction is responsible for B-cell acute lymphoblastic leukemia caused by JAK2 R683G(S) mutations.
Wu QY; Guo HY; Li F; Li ZY; Zeng LY; Xu KL
Leuk Lymphoma; 2013 Dec; 54(12):2693-700. PubMed ID: 23452118
[TBL] [Abstract][Full Text] [Related]
3. Effects of the I682F mutation on JAK2's activity, structure and stability.
Li F; Li W; Liu Y; Tong YX; Zhou P; Wang L; Chen C; Zeng LY; Wu QY; Wang XY; Xu KL
Int J Biol Macromol; 2015 Aug; 79():118-25. PubMed ID: 25940527
[TBL] [Abstract][Full Text] [Related]
4. New insights into the structure and function of the pseudokinase domain in JAK2.
Silvennoinen O; Ungureanu D; Niranjan Y; Hammaren H; Bandaranayake R; Hubbard SR
Biochem Soc Trans; 2013 Aug; 41(4):1002-7. PubMed ID: 23863170
[TBL] [Abstract][Full Text] [Related]
5. Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.
Hammarén HM; Virtanen AT; Abraham BG; Peussa H; Hubbard SR; Silvennoinen O
J Allergy Clin Immunol; 2019 Apr; 143(4):1549-1559.e6. PubMed ID: 30092288
[TBL] [Abstract][Full Text] [Related]
6. Amino acid residue E543 in JAK2 C618R is a potential therapeutic target for myeloproliferative disorders caused by JAK2 C618R mutation.
Wu QY; Li F; Guo HY; Cao J; Chen C; Chen W; Zhao K; Zeng LY; Han ZX; Li ZY; Wang XY; Xu KL
Arch Biochem Biophys; 2012 Dec; 528(1):57-66. PubMed ID: 22960131
[TBL] [Abstract][Full Text] [Related]
7. Roles of T875N somatic mutation in the activity, structural stability of JAK2 and the transformation of OCI-AML3 cells.
Chen C; Li F; Ma MM; Zhang S; Liu Y; Yan ZL; Chen W; Cao J; Zeng LY; Wang XY; Xu KL; Wu QY
Int J Biol Macromol; 2019 Sep; 137():1030-1040. PubMed ID: 31299252
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of constitutive activation of Janus kinase 2-V617F revealed at the atomic level through molecular dynamics simulations.
Lee TS; Ma W; Zhang X; Giles F; Kantarjian H; Albitar M
Cancer; 2009 Apr; 115(8):1692-700. PubMed ID: 19195039
[TBL] [Abstract][Full Text] [Related]
9. ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation.
Hammarén HM; Ungureanu D; Grisouard J; Skoda RC; Hubbard SR; Silvennoinen O
Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4642-7. PubMed ID: 25825724
[TBL] [Abstract][Full Text] [Related]
10. Regulation of JAK2 activation by Janus homology 2: evidence from molecular dynamics simulations.
Wan S; Coveney PV
J Chem Inf Model; 2012 Nov; 52(11):2992-3000. PubMed ID: 23033920
[TBL] [Abstract][Full Text] [Related]
11. Effects of JAK2 V556F mutation on the JAK2's activity, structural stability and the transformation of Ba/F3 cells.
Wu QY; Ma MM; Tong YX; Zhu YY; Liu Y; Cao J; Zhou P; Li ZY; Zeng LY; Wang XY; Li F; Xu KL
Int J Biol Macromol; 2018 Oct; 117():271-279. PubMed ID: 29842959
[TBL] [Abstract][Full Text] [Related]
12. [Research advances in the role of JAK2 mutations in acute leukemia].
Zhang HY; Zhai XW
Zhongguo Dang Dai Er Ke Za Zhi; 2015 Jun; 17(6):644-9. PubMed ID: 26108332
[TBL] [Abstract][Full Text] [Related]
13. Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).
Min X; Ungureanu D; Maxwell S; Hammarén H; Thibault S; Hillert EK; Ayres M; Greenfield B; Eksterowicz J; Gabel C; Walker N; Silvennoinen O; Wang Z
J Biol Chem; 2015 Nov; 290(45):27261-27270. PubMed ID: 26359499
[TBL] [Abstract][Full Text] [Related]
14. Disruption of R867 and Y613 interaction plays key roles in JAK2 R867Q mutation caused acute leukemia.
Wu QY; Ma MM; Zhang S; Cao J; Yan ZL; Chen C; Li ZY; Zeng LY; Wang XY; Li F; Xu KL
Int J Biol Macromol; 2019 Sep; 136():209-219. PubMed ID: 31199972
[TBL] [Abstract][Full Text] [Related]
15. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome.
Bercovich D; Ganmore I; Scott LM; Wainreb G; Birger Y; Elimelech A; Shochat C; Cazzaniga G; Biondi A; Basso G; Cario G; Schrappe M; Stanulla M; Strehl S; Haas OA; Mann G; Binder V; Borkhardt A; Kempski H; Trka J; Bielorei B; Avigad S; Stark B; Smith O; Dastugue N; Bourquin JP; Tal NB; Green AR; Izraeli S
Lancet; 2008 Oct; 372(9648):1484-92. PubMed ID: 18805579
[TBL] [Abstract][Full Text] [Related]
16. Roles of germline JAK2 activation mutation JAK2 V625F in the pathology of myeloproliferative neoplasms.
Wu QY; Ma MM; Fu L; Zhu YY; Liu Y; Cao J; Zhou P; Li ZY; Zeng LY; Li F; Wang XY; Xu KL
Int J Biol Macromol; 2018 Sep; 116():1064-1073. PubMed ID: 29782975
[TBL] [Abstract][Full Text] [Related]
17. Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F.
Bandaranayake RM; Ungureanu D; Shan Y; Shaw DE; Silvennoinen O; Hubbard SR
Nat Struct Mol Biol; 2012 Aug; 19(8):754-9. PubMed ID: 22820988
[TBL] [Abstract][Full Text] [Related]
18. JAK/STAT signaling in hematological malignancies.
Vainchenker W; Constantinescu SN
Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
[TBL] [Abstract][Full Text] [Related]
19. Loss of K607 and E877 interaction is a key reason for JAK2 K607N mutation caused acute myeloid leukemia.
Wu QY; Ma MM; Zhang S; Liu Y; Cao J; Yan ZL; Li ZY; Zeng LY; Wang XY; Li F; Xu KL
Int J Biol Macromol; 2019 Mar; 124():1123-1131. PubMed ID: 30521925
[TBL] [Abstract][Full Text] [Related]
20. JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors.
Dusa A; Mouton C; Pecquet C; Herman M; Constantinescu SN
PLoS One; 2010 Jun; 5(6):e11157. PubMed ID: 20585391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
